Connect
MJA
MJA

In Other Journals

Ann Gregory
Med J Aust 2005; 182 (9): . || doi: 10.5694/j.1326-5377.2005.tb06775.x
Published online: 2 May 2005

Anti-obesity drugs, in general, lead to only a modest weight loss of about 5 kg or less at 1 year, according to a meta-analysis of data from more than 75 clinical trials. The US researchers who reported the meta-analysis results examined not only agents specifically approved for use in obesity, such as orlistat and sibutramine, but also other medications being used for weight loss, including sertraline, fluoxetine and bupropion. Despite the somewhat disappointing overall finding, the researchers said this modest amount of weight loss may still be clinically significant. They said the choice of medication for weight loss probably depended on the patient’s tolerance to the side effect profile of each agent.




Correspondence: 

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.